<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01159873</url>
  </required_header>
  <id_info>
    <org_study_id>C37251/1080</org_study_id>
    <nct_id>NCT01159873</nct_id>
  </id_info>
  <brief_title>Single Ascending-Dose Study to Characterize the Safety, Pharmacokinetics, and Pharmacodynamics of CEP-37251 in Healthy Postmenopausal Women</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Single Ascending-Dose Study to Characterize the Safety, Pharmacokinetics, and Pharmacodynamics of CEP-37251 in Healthy Postmenopausal Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cephalon</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Branded Pharmaceutical Products R&amp;D, Inc.</source>
  <brief_summary>
    <textblock>
      Study to Characterize the Safety, Pharmacokinetics, and Pharmacodynamics of CEP-37251 in&#xD;
      Healthy Postmenopausal Women.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study has been stopped by sponsor decision&#xD;
  </why_stopped>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Characterize the Overall Safety Assessment of CEP-37251</measure>
    <time_frame>70 days</time_frame>
    <description>Measurements include adverse events, laboratory results, vital sign measurements, electrocardiogram findings, physical examination findings, injection site evaluations, concomitant medication usage, immunophenotyping test results, and immunogenicity test results.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Characterize the Overall Pharmacokinetic Profile of CEP-37251</measure>
    <time_frame>70 days</time_frame>
    <description>Pharmacokinetic parameters include Cmax (Maximum Concentration) and AUC (Area Under the Curve) plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize the Overall Pharmacodynamic Effect of CEP-37251</measure>
    <time_frame>70 days</time_frame>
    <description>Pharmacodynamic effect as measured by markers of bone metabolism</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Bone Loss</condition>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>CEP-37251</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CEP-37251</intervention_name>
    <description>up to 5 subcutaneous (sc) doses (given sequentially in cohort groups) of CEP-37251 (0.03, 0.1, 0.3, 1.0, and 3.0 mg/kg) will be studied. After all 5 sc doses have been studied, an intravenous (iv) dose of 0.3 mg/kg will be studied.</description>
    <arm_group_label>CEP-37251</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>up to 5 subcutaneous (sc) doses (given sequentially in cohort groups) of Placebo (0.03, 0.1, 0.3, 1.0, and 3.0 mg/kg) will be studied. After all 5 sc doses have been studied, an intravenous (iv) placebo dose of 0.3 mg/kg will be studied.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The subject is a postmenopausal woman aged 40 years or greater but less than 75 years.&#xD;
&#xD;
          -  The subject is ambulatory and healthy as judged by medical examination, medical&#xD;
             history, and clinical chemistry, hematology and urinalysis at screening.&#xD;
&#xD;
          -  The subject has a body weight greater than 50 kg but no more than 100 kg with a body&#xD;
             mass index (BMI) of 18 to 35 kg/m2).&#xD;
&#xD;
          -  The subject has a normal or clinically acceptable ECG.&#xD;
&#xD;
          -  The subject is willing to give written informed consent prior to any study-related&#xD;
             procedures being conducted.&#xD;
&#xD;
          -  The subject is willing and able to comply with the study restrictions and to remain in&#xD;
             the study center for the required inpatient period.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The subject has received any of the following medications within the 6 months prior to&#xD;
             enrollment:&#xD;
&#xD;
               -  hormone replacement therapy&#xD;
&#xD;
               -  selective estrogen receptor modulator (SERM) therapy such as raloxifene&#xD;
&#xD;
               -  elemental calcium supplementation &gt;1.5 g/day&#xD;
&#xD;
               -  Vitamin D supplementation &gt;1000 IU per day&#xD;
&#xD;
               -  calcitriol or other Vitamin D analogs (eg, alfacalcidol, doxercalciferol, or&#xD;
                  paricalcitol)&#xD;
&#xD;
               -  calcitonin or parathyroid hormone&#xD;
&#xD;
               -  chronic use of glucocorticoids NOTE: Acute use of glucocorticoids may be&#xD;
                  permitted after consultation with the medical monitor if it occurred a minimum of&#xD;
                  6 weeks prior to enrollment&#xD;
&#xD;
               -  anabolic steroids&#xD;
&#xD;
          -  The subject has received bisphosphonates or fluoride within the 12 months prior to&#xD;
             enrollment.&#xD;
&#xD;
          -  The subject has any of the following concomitant conditions:&#xD;
&#xD;
               -  hypo- or hyperthyroidism. NOTE: Subjects with treated hypothyroidism with normal&#xD;
                  thyroid parameters may be allowed to participate in the study at the discretion&#xD;
                  of the investigator and medical monitor.&#xD;
&#xD;
               -  hypo- or hyperparathyroidism&#xD;
&#xD;
               -  recent fracture (within 6 months)&#xD;
&#xD;
               -  osteomalacia, Paget's Disease, osteopetrosis, osteogenesis imperfect, or other&#xD;
                  bone disease&#xD;
&#xD;
               -  rheumatoid arthritis or psoriatic arthritis&#xD;
&#xD;
               -  acute osteoarthritis or gout&#xD;
&#xD;
               -  chronic kidney disease or renal failure defined as an eGFR (by MDRD equation) 30&#xD;
                  mL/min/1.73 m2 or less&#xD;
&#xD;
          -  The subject is receiving immunosuppressant drugs.&#xD;
&#xD;
          -  The subject is currently participating in another investigational study or has&#xD;
             received any investigational drug within 60 days before the dose of study drug.&#xD;
&#xD;
          -  The subject has evidence of severe, progressive, or uncontrolled renal, hepatic,&#xD;
             hematologic, gastrointestinal, endocrine, pulmonary, cardiac, neurologic, psychiatric,&#xD;
             or cerebral disease, or malabsorption syndrome.&#xD;
&#xD;
          -  The subject has a known history or evidence of malignancy, lymphoproliferative, or&#xD;
             neoplastic disease with the exception of being successfully treated for basal or&#xD;
             squamous cell carcinoma of the skin or cervical intraepithelial neoplasia.&#xD;
&#xD;
          -  The subject has had any substantial change in levels of physical activity or&#xD;
             participated in intense physical activity (e.g., marathon training) within the 6&#xD;
             months prior to the dose of study drug.&#xD;
&#xD;
          -  The subject has any other clinically significant disease or disorder or factors, such&#xD;
             as substance abuse, which in the opinion of the investigator, make the subject&#xD;
             ineligible for participation in this study.&#xD;
&#xD;
          -  The subject has a known or suspected hypersensitivity or idiosyncratic reaction to any&#xD;
             compound present in the study drug or placebo.&#xD;
&#xD;
          -  The subject has habitually consumed, within the past 2 years, more than 21 units of&#xD;
             alcohol per week, or has a history of alcohol, narcotic, or any other substance abuse&#xD;
             as defined by the Diagnostic and Statistical Manual of Mental Disorders, Fourth&#xD;
             Edition, Text Revision (DSM-IV-TR). NOTE: A unit of alcohol is equal to approximately&#xD;
             30 ml of spirits, 100 ml of wine, or 260 ml of full-strength beer.&#xD;
&#xD;
          -  The subject has, within 2 weeks before administration of the dose of study drug, a&#xD;
             clinically significant excessive consumption of coffee, tea, and/or other&#xD;
             caffeine-containing beverage or food (i.e., 600 mg of caffeine or more per day, or 5&#xD;
             or more cups of coffee per day), or a combination of any of these beverages or foods.&#xD;
&#xD;
          -  The subject has had, within 4 weeks before the dose of study drug, a clinically&#xD;
             significant illness or, within 1 week before the dose of study drug, has had any acute&#xD;
             illness, or at screening or on the day before the dose of study drug, has symptoms of&#xD;
             any clinically significant or acute illness.&#xD;
&#xD;
          -  The subject has, after resting for 5 minutes, elevated blood pressure (defined as a&#xD;
             systolic blood pressure of more than 140 mm Hg for subjects ≤50 years of age or 155 mm&#xD;
             Hg for subjects &gt;50 years of age and/or a diastolic blood pressure of more than 90 mm&#xD;
             Hg) or has low blood pressure (defined as systolic blood pressure of less than 90 mm&#xD;
             Hg and/or diastolic blood pressure of less than 45 mm Hg).&#xD;
&#xD;
          -  The subject has, after resting for 5 minutes, a pulse less than 45 beats per minute&#xD;
             (bpm). The subject has, after resting for 5 minutes, a pulse more than 90 bpm for&#xD;
             subjects ≤50 years of age or a pulse more than 100 bpm for subjects &gt;50 years of age.&#xD;
&#xD;
          -  The subject has a positive test result for hepatitis B surface antigen (HBsAg) or&#xD;
             antibodies to hepatitis C or human immunodeficiency virus (HIV).&#xD;
&#xD;
          -  History of any clinically important drug and/or vaccine allergies.&#xD;
&#xD;
          -  The subject has received immunization with a live or live attenuated vaccine within 3&#xD;
             months prior to the dose of study drug or has immunization with a live or live&#xD;
             attenuated vaccine planned within 3 months after the dose of study drug.&#xD;
&#xD;
          -  The subject has an ongoing active systemic infection requiring treatment or a history&#xD;
             of severe infection, such as hepatitis or pneumonia, in the 3 months prior to the dose&#xD;
             of study drug. Less severe infections in the 3 months prior to the dose of study drug&#xD;
             are permitted at the discretion of the investigator and medical monitor.&#xD;
&#xD;
          -  The subject has a positive alcohol serum, urine, or breath test result or a positive&#xD;
             urine drug screen (UDS).&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sr. Director, Clinical Pharmacology and Experimental Medicine, MD</last_name>
    <role>Study Director</role>
    <affiliation>Cephalon</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cephalon Investigational Site</name>
      <address>
        <city>Adelaide</city>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <study_first_submitted>July 8, 2010</study_first_submitted>
  <study_first_submitted_qc>July 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2010</study_first_posted>
  <last_update_submitted>May 9, 2014</last_update_submitted>
  <last_update_submitted_qc>May 9, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 12, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

